Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -60.93% is 60% above its 5-year average of -152.09%, near the high end of its 5-year range (-354.19%–-25.73%).
61.98% above its 12-month average of -160.25%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -18.92%.
RETURN ON ASSETS (ROA)
-60.93%
RETURN ON ASSETS (ROA) AVG TTM
-160.25%
RETURN ON ASSETS (ROA) AVG 3Y
-205.49%
RETURN ON ASSETS (ROA) AVG 5Y
-152.09%
RETURN ON ASSETS (ROA) AVG 10Y
-121.23%
RETURN ON ASSETS (ROA) AVG 15Y
-96.07%
RETURN ON ASSETS (ROA) AVG 20Y
-105.65%
CURRENT VS TTM AVG
+61.98%
CURRENT VS 3Y AVG
+70.35%
CURRENT VS 5Y AVG
+59.94%
CURRENT VS 10Y AVG
+49.74%
CURRENT VS 15Y AVG
+36.58%
CURRENT VS 20Y AVG
+42.33%
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-88.84%
vs the sector median at left
Cellectar Biosciences, Inc.
Market Cap
$12.06M
Return on Assets (ROA)
-60.93%
TTM Avg
-160.25%
3Y Avg
-205.49%
5Y Avg
-152.09%
Market Cap
$12.17M
Return on Assets (ROA)
-216.84%
TTM Avg
-118.20%
3Y Avg
-6127.40%
5Y Avg
-4092.56%
Market Cap
$11.93M
Return on Assets (ROA)
-26.45%
TTM Avg
-58.62%
3Y Avg
-47.64%
5Y Avg
-51.16%
Market Cap
$11.77M
Return on Assets (ROA)
-13.01%
TTM Avg
-15.22%
3Y Avg
-24.53%
5Y Avg
-20.43%
Market Cap
$12.44M
Return on Assets (ROA)
-47.98%
TTM Avg
-31.15%
3Y Avg
-42.27%
5Y Avg
-34.21%
Market Cap
$12.48M
Return on Assets (ROA)
-49.12%
TTM Avg
-29.80%
3Y Avg
-67.98%
5Y Avg
-117.36%
Market Cap
$11.55M
Return on Assets (ROA)
-90.19%
TTM Avg
-82.55%
3Y Avg
-92.57%
5Y Avg
-79.83%
Market Cap
$12.58M
Return on Assets (ROA)
-420.14%
TTM Avg
-127.99%
3Y Avg
-97.65%
5Y Avg
-85.48%
Market Cap
$11.36M
Return on Assets (ROA)
-404.58%
TTM Avg
-269.82%
3Y Avg
-269.82%
5Y Avg
-269.82%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cellectar Biosciences, Inc. (CLRB) | $12.06M | -60.93% | -160.25% | -205.49% | -152.09% |
| Lantern Pharma Inc. (LTRN)vs › | $12.17M | -216.84% | -118.20% | -6127.40% | -4092.56% |
| Biofrontera Inc. (BFRI)vs › | $11.93M | -26.45% | -58.62% | -47.64% | -51.16% |
| IRIDEX Corporation (IRIX)vs › | $11.77M | -13.01% | -15.22% | -24.53% | -20.43% |
| Cytosorbents Corporation (CTSO)vs › | $12.44M | -47.98% | -31.15% | -42.27% | -34.21% |
| Dare Bioscience, Inc. (DARE)vs › | $12.48M | -49.12% | -29.80% | -67.98% | -117.36% |
| Phio Pharmaceuticals Corp. (PHIO)vs › | $11.55M | -90.19% | -82.55% | -92.57% | -79.83% |
| Tempest Therapeutics, Inc. (TPST)vs › | $12.58M | -420.14% | -127.99% | -97.65% | -85.48% |
| Caring Brands, Inc. (CABR)vs › | $11.36M | -404.58% | -269.82% | -269.82% | -269.82% |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $12.78M | -77.94% | -178.68% | -1009.31% | -2782.57% |
ROA
-60.9%
ROE
-74.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -145.48% |
| 2024-12-31 | -175.01% |
| 2023-12-31 | -354.19% |
| 2022-12-31 | -147.26% |
| 2021-12-31 | -64.84% |
| 2020-12-31 | -25.73% |
| 2019-12-31 | -115.04% |
| 2018-12-31 | -87.94% |
| 2017-12-31 | -105.37% |
| 2016-12-31 | -40.33% |
| 2015-12-31 | -72.34% |
| 2014-12-31 | -60.41% |
| 2013-12-31 | -158.19% |
| 2012-12-31 | -76.64% |
| 2011-12-31 | -70.39% |
| 2010-12-31 | 85.16% |
| 2009-12-31 | -249.37% |
| 2008-12-31 | -1122.17% |
| 2007-12-31 | -176.07% |
| 2006-12-31 | -69.49% |
| 2005-12-31 | -61.83% |
| 2004-12-31 | -750.92% |
